10x Genomics Inc. (TXG)
10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.53 per share a year ago.
Unlocking Q2 Potential of 10x Genomics (TXG): Exploring Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does 10x Genomics (TXG) Have the Potential to Rally 85.65% as Wall Street Analysts Expect?
The consensus price target hints at an 85.7% upside potential for 10x Genomics (TXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
10x Genomics (TXG) Surges 8.2%: Is This an Indication of Further Gains?
10x Genomics (TXG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
10x Genomics: Sticking To The Plan To Avoid The Falling The Knife
10x Genomics has experienced a significant decline in share price, currently trading around $20 per share, with no bullish indicators for a potential reversal. Recent performance shows growth in total revenue to $141M, but with a decrease in consumables revenue and a rise in operating costs, leading to an operating loss. Factors contributing to the decline in TXG include economic influences, fading growth prospects, supply chain issues, legal battles with NanoString Technologies, and a lack of retail investor interest.
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of 10x Genomics, Inc. (NASDAQ: TXG) and Encourages Investors to Contact the Firm
PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating 10x Genomics, Inc. (NASDAQ:TXG) on behalf of the company's stockholders. The investigation seeks to determine whether 10x Genomics and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's investors in connection with recent corporate actions.
